FindMyRecallSubscribe
Class III: unlikely to cause harmTerminated

Taro Pharmaceuticals U.S.A. Clotrimazole and Betamethasone Dipropionate Recall

Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0

Taro Pharmaceuticals U.S.A., Inc. · Hawthorne, NY

Risk level
Class III
Reported by FDA
Apr 6, 2022
Recall ID
D-0727-2022
Check your lot numberHow we source this data

Summary

Taro Pharmaceuticals U.S.A. recalled Clotrimazole and Betamethasone Dipropionate starting Feb 25, 2022. The FDA classified it as Class III (unlikely to cause harm) and published enforcement report D-0727-2022 on Apr 6, 2022. Reason: Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample. Status: Terminated.

Why it was recalled

Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample

Product description

Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, Rx only, Manufactured by: Taro Pharmaceuticals Industries Ltd. Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4048-1

Lot numbers, UPCs & expiration codes

Lot #: AC33883, Exp. Date June 2023

Where it was sold

Product was distributed to one retail consignee in NY.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0727-2022
Classification
Class III
Status
Terminated
Recall initiated
Feb 25, 2022
FDA report date
Apr 6, 2022
Quantity
768 tubes
Recall type
Voluntary: Firm initiated
Recalling firm
Taro Pharmaceuticals U.S.A., Inc.

Original FDA data

Every field from FDA enforcement report D-0727-2022, exactly as published.

Show all FDA fields
City
Hawthorne
State
NY
Status
Terminated
Country
United States
Event ID
89678
Address
3 Skyline Dr
Code information
Lot #: AC33883, Exp. Date June 2023
Postal code
10532-2174
Report date
Apr 6, 2022
Product type
Drugs
Recall number
D-0727-2022
Classification
Class III
Recalling firm
Taro Pharmaceuticals U.S.A., Inc.
Product quantity
768 tubes
Termination date
Sep 9, 2024
Reason for recall
Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample
Voluntary / mandated
Voluntary: Firm initiated
Product description
Clotrimazole and Betamethasone Dipropionate Cream USP, 1%/0.05%,15 g tubes, Rx only, Manufactured by: Taro Pharmaceuticals Industries Ltd. Haifa Bay, Israel 2624761, Distributed by: Taro Pharmaceuticals U.S.A., Inc. Hawthorne, NY 10532, NDC 51672-4048-1
Distribution pattern
Product was distributed to one retail consignee in NY.
Recall initiation date
Feb 25, 2022
Initial firm notification
Letter
Center classification date
Mar 29, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0727-2022, published Apr 6, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls